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Free fatty acids (FFAs) play a pivotal role in metabolic control and cell signaling processes in
various tissues. In particular, FFAs are known to augment glucose-stimulated insulin secre-
tion by pancreatic beta cells, where fatty acid-derived metabolites, such as long-chain fatty
acyl-CoAs, are believed to act as crucial effectors. Recently, G-protein-coupled receptor
40 (GPR40), a receptor for long-chain fatty acids, was reported to be highly expressed in
pancreatic beta cells and involved in the regulation of insulin secretion. Hence, GPR40 is
considered to be a potential therapeutic target for the treatment of diabetes. In this review,
we summarize the identification and gene expression patterns of GPR40 and its role in glu-
cose metabolism. We also discuss the potential application of GPR40 as a therapeutic
target.
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INTRODUCTION
Free fatty acids (FFAs) are essential nutrients that also act as
signaling molecules in various tissues. Long-chain fatty acids
(LCFAs) play a role in the augmentation of glucose-stimulated
insulin secretion (GSIS) (1). GSIS was observed to be consider-
ably decreased by FFA depletion following in vivo administration
of nicotinic acid to rats (2) and humans (3). Thus, FFA-mediated
augmentation is considered to be physiologically significant. How-
ever, the underlying mechanisms of FFA-mediated augmentation
of GSIS have not been fully elucidated. Several investigators have
recently demonstrated that FFAs act as ligands for membrane-
bound G-protein-coupled receptors (GPCRs) such as G-protein-
coupled receptor 40 (GPR40), GPR41, GPR43, and GPR120.
Among these, GPR40 is preferentially expressed by pancreatic beta
cells in rodents and augments GSIS after acute exposure to LCFAs,
highlighting the role of GPR40 as a potential key molecule in the
regulation of insulin secretion.
LCFA RECEPTOR GPR40
GPR40 consists of 300 residues and was originally reported as an
orphan GPCR (4). GPR40 was deorphaned by screening using a
fluorometric imaging plate reader (FLIPR) system, which detects
increases in Ca2+ concentrations in cultured cells with transiently
expressed GPR40 cDNA (5, 6). GPR40 is reportedly activated by
LCFAs (C12–22) and several eicosanoids in theoretically phys-
iological concentration ranges. The profiles of putative GPR40
ligands are well conserved among mice, rats, and humans (5).
GPR40 GENE EXPRESSION IN RODENTS
Among rat tissues, GPR40 mRNA is almost exclusively expressed in
the pancreas. In pancreatic islets, GPR40 mRNA levels were found
to be approximately 17-fold higher than the levels in the pan-
creas, suggesting selective GPR40 expression by pancreatic islets.
Considerable amounts of GPR40 mRNA were detected in the pan-
creatic beta cell lines MIN6, betaTC-3, HIT-T15, and Rin5F but
not in the pancreatic alpha cell line alphaTC1. Furthermore, in situ
hybridization with rat pancreatic islets suggested that GPR40
mRNA is preferentially expressed in pancreatic beta cells (5).
Reports using anti-GPR40 antibodies suggest that GPR40
protein is also probably preferentially expressed in pancreatic
islets (7, 8).
ROLES OF GPR40 IN REGULATION OF INSULIN SECRETION
In MIN6 cells, insulin secretion was augmented by LCFAs in
a dose-dependent manner, and the augmentation was observed
only under hyperglycemic conditions (11–22 mM) (5), indicating
the LCFA-mediated augmentation of insulin secretion is glucose-
dependent. Silencing of GPR40 gene expression using siRNA
almost abolished the augmentation effects of LCFAs, indicating
that GPR40 is involved in LCFA-mediated regulation of insulin
secretion. GPR40 is a class A GPCR, highlighting the potential of
GPR40 as a target for novel anti-diabetic oral drugs with low risk
of hypoglycemia, considering that LCFA-mediated augmentation
of insulin secretion is glucose-dependent.
GPR40 GENE EXPRESSION IN HUMANS
Although GPR40 is reportedly preferentially expressed by pancre-
atic beta cells in both rats and mice, little is known about GPR40
gene expression in humans. In this context, we assessed GPR40
mRNA expression in fresh human tissues obtained during surgery
(9, 10). Analysis of 12 specimens of non-tumor pancreatic tis-
sues revealed a considerable amount of GPR40 mRNA in each.
In three pancreatic islet tissues specimens, GPR40 mRNA levels
were approximately 20-fold higher than those in pancreatic tis-
sues, comparable to the levels of sulfonylurea receptor 1, which is
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known to be highly expressed in pancreatic beta cells. High levels
of GPR40 mRNA were detected in insulinoma (beta cell tumor)
tissues in three cases; in contrast, GPR40 mRNA was undetectable
in glucagonoma (alpha cell tumor) tissues (10, 11). In human pan-
creas, GPR40 mRNA level is positively and significantly correlated
with the insulinogenic index, an index reflecting the function of
pancreatic beta cells. These results indicate that GPR40 is highly
expressed in human pancreatic beta cells and possibly involved in
the positive regulation of insulin secretion (10).
REGULATION OF GPR40 GENE EXPRESSION
Though the mechanisms underlying the regulation of GPR40 gene
expression is not fully understood, possible mechanisms include
the PDX-1/IPF1 (12), which reportedly binds to the promoter
region of the GPR40 gene (13). Moreover, nutrients and therapeu-
tic drugs such as glucose (12), palmitate, and rosiglitazone (8) are
reportedly involved in the regulation of GPR40 gene expressions.
THERAPEUTIC IMPLICATIONS OF GPR40
Although an initial report of systemic GPR40 knockout (KO) mice
and beta cell-specific GPR40 transgenic (Tg) mice using the PDX-
1/IPF1 promoter suggested possible involvement of GPR40 in
insulin resistance in the liver and beta cell failure (14), later reports
using GPR40 KO mice found no link between GPR40 and beta cell
dysfunction (15, 16). Studies using GPR40 KO mice suggest the
implication of GPR40 in the regulation of insulin secretion, at
least under some conditions including loading of intralipid (17),
high-fat diet (15), hyperglycemic glucose clamp, and arginine (18).
Furthermore, GPR40 Tg mice with the mouse INS2 promoter
exhibited better glucose tolerance with enhanced GSIS (19), sug-
gesting therapeutic implications of GPR40 rather than a gateway
of beta cell toxicity.
Additionally, recent reports suggest that GPR40 is expressed
in enteroendocrine cells and involved in the positive regula-
tion of intestinal hormones including glucagon-like peptide-1
(GLP-1), glucose-dependent insulinotropic polypeptide (GIP),
and cholecystokinin (20–22).
GPR40 AGONISTS AS ANTI-DIABETIC DRUGS
Recently, TAK-875 (Fasiglifam), a novel GPR40 selective agonist
(23), was reported as a potential oral anti-diabetic drug. The
potency of TAK-875 is approximately 400-fold greater than that
of the endogenous ligand oleic acid (24), and it does not acti-
vate GPR120 (23), another GPCR for LCFAs. TAK-875 augmented
insulin secretion under high-glucose conditions in the rat pancre-
atic beta cell line INS1 833/14 (24) and human pancreatic islets
(25) but did not affect glucagon secretion in humans (25), in accor-
dance with the observations in humans by our group and others
(9–11). TAK-875 significantly improved glycemic control with the
augmentation of insulin secretion in diabetic rat models such as
Wistar fatty rats (23) and Zucker diabetic fatty rats (24).
In phase 2, randomized, double-blind, placebo-controlled trial
in patients with type 2 diabetes, HbA1c was decreased in a dose-
dependent manner in TAK-875 groups, and the HbA1c-lowering
effect (50–200 mg, approximately −1.1% in 12 weeks) was com-
parable to that in glimepiride (4 mg) group, while the incidence
of hypoglycemia in TAK-875 was similar to the placebo group
FIGURE 1 | LCFAs augment insulin secretion by stimulating GPR40 in
beta cells in the pancreas. GPR40 is also reportedly involved in the positive
regulation of secretion of some intestinal hormones. Studies using GPR40
agonists and analyses of beta cell-specific GPR40 transgenic mice indicate
that GPR40 is involved in the regulation of glucose metabolism, at least by
the augmentation of insulin secretion. Because LCFA-mediated augmentation
of insulin secretion is glucose-dependent, GPR40 is thought to be a potential
target for novel anti-diabetic drugs with low risk of hypoglycemia.
and markedly lower than the glimepiride group (26). In Japanese
patients with type 2 diabetes, 12-week treatment with TAK-875
also decreased HbA1c levels in a dose-dependent manner, and the
HbA1c-lowering effect (50–200 mg, approximately −1.3%) was
comparable to that in the glimepiride (1 mg) group (27).
Though TAK-875 seemed to be a promising anti-diabetic drug,
regrettably, its development was terminated in 2013 because of the
risk of possible liver damage. Although the cause of the liver dam-
age remains unclear, GPR40 is not expressed in the human liver
(6, 10), suggesting that the toxicity may not be due to the GPR40
receptor itself but chemical characteristic of TAK-875 or its dose
used in the clinical trials. Still, several GPR40 agonists continue
to be evaluated in both preclinical (Bristol-Myers Squibb, Merck,
Amgen, Johnson & Johnson, Astellas, Daiichi Sankyo, Piramal, and
Connexios) and clinical (Japan Tobacco) trials, and the further
development is expected in the study elucidating the significance
of GPR40 in glucose and other metabolism.
CONCLUSION
Incretin mimetic-type drugs have been implicated in GPCR-
mediated regulation of insulin secretion in diabetes. GPR40 is a
GPCR that is highly expressed in pancreatic beta cells and involved
in insulin secretion in rodents and humans. Hence, GPR40 is
a potential therapeutic target in diabetes, which can lead to the
development of oral drugs with fewer hypoglycemic side effects.
Furthermore, GPR40 is reportedly implicated in the regulation
of incretin secretion from enteroendocrine cells. GPR40 may be
important to unveil the link between FFA signaling and beta
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cell function as well as glucose metabolism (Figure 1). Hence,
further studies are warranted to elucidate the physiological and
pathophysiological implications of GPR40.
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